Background: Dendritic cells (DC) can act tolerogenic at a semi-mature stage by induction of protective CD4
Introduction
DC are not only potent inducers of adaptive immune responses but also mediators of tolerance. Immature DC, which do not express maturation markers and produce no cytokines are considered to be tolerogenic. Fully mature DC upregulate maturation markers upon stimulation and produce cytokines and are therefore termed immunogenic. In addition another maturation stage has been characterized as semi-mature DC [1] . These cells which upregulate maturation markers but do not produce cytokines are tolerogenic and can protect mice from EAE by inducing protective CD4 + T cell and NKT cells responses [2, 3] .
For efficient T cell activation and the generation of functionally competent effector cells, additional costimulatory signaling through surface molecules on APC and T cells is needed [4] . Upregulation of T cell activity by attenuation of coinhibitory signals provides an attractive tool for the treatment of autoimmune and inflammatory diseases [5] . Among the B7-CD28 family of costimulatory molecules, B7-H1 on APC has been proposed to regulate immune responses by interaction with PD-1 or CD80 (B7-1) and possibly another yet unidentified receptor on activated T cells [6, 7, 8] . B7-H1 is widely expressed on different cell populations including T and B cells, monocytes, DC, but also non-hematopoietic cells [9, 10] . Its receptor PD-1 is inducible on T and B cells upon activation [11] . Due to their broad tissue expression pattern, B7-H1/PD-1 interactions have been implicated in critically modulating parenchymal inflammation, limiting autoimmune responses and confining immune cell functions in the periphery [12, 13, 14, 15] .
Originally, interactions of B7-H1/PD-1 were postulated to costimulate T cell activation and proliferation [16] , but more recent data point towards a negative regulatory role of the B7-H1/ PD-1 pathway in T cell activation, proliferation and CTL activity [6, 9, 17, 18] . Using the animal model of MS, EAE, this coinhibitory effect mediated by B7-H1 has been extensively studied [12, 15, 19, 20, 21, 22] . It was demonstrated that systemic absence of B7-H1 renders 129Sv mice susceptible to EAE and exacerbates disease in C57BL/6 mice [6, 15, 21] . Additionally, blockade of B7-H1 or PD-1 with specific antibodies resulted in increased susceptibility and progression of EAE in various mouse strains [20, 23] . While B7-H1 expression in the CNS was shown to be very limited under physiological conditions, it is rapidly upregulated during inflammation [19] . Particularly microglial cells expressing inhibitory B7-H1 were found to dampen encephalitogenic T cell responses in later stages of EAE, suggesting a major contribution of this molecule to confinement of parenchymal inflammation [12, 22] . Similar conclusions were drawn from experiments using an animal model of diabetes, where PD-1/B7-H1 interactions were shown to regulate effector cell differentiation of autoreactive CD8 + T cells during the presentation of tissue antigens [13] . However, little is known about the role of the B7-H1/PD-1 pathway in mediating tolerogenicity during protection against neuroinflammation.
In this study, we investigated the role of B7-H1 on tolerogenic DC in mediating tolerance induction in the context of autoimmune inflammation. After intravenous injections of TNF-treated semimature DC deficient in B7-H1 we found a stronger tolerogenic capacity in EAE protection in comparison to WT DC. In the CNS, we found no differences in total CD4 and CD8 T cell infiltration, but lower numbers of neuroantigen-specific IFN-c and IL-17 producing cells. The ameliorated EAE phenotype was accompanied by increased production of the protective cytokines IL-10 and IL-13 and reduced levels of proinflammatory IFN-c and IL-17 in the periphery. Additionally, we observed higher serum cytokine levels of IL-4 and IL-13 in B7-H1 2/2 DC injected mice, which contributed to the tolerance induction. We found that type II cells but not type I invariant NKT (iNKT) cells were the producers of these cytokines. It has been described that the B7-H1/PD1 pathway is involved in the activation of iNKT cells [24, 25] . We found that the signaling via B7-H1 on the DC does not influence the iNKT response but it has an impact on other CD1d-restricted cells. It has been shown that in mice lacking the MHC class II molecule there is still a population of T cells other than iNKT cells, which recognize the CD1d molecule. Now we show that these type II NKT cells are regulated by B7-H1 [26, 27] . Our data describe the importance of B7-H1/type II NKT cell interactions and its unexpected impact by modulation of tolerogenic DC in EAE protection.
Results

DC from WT and B7-H1
2/2 mice show a similar expression of surface markers and have the same potential to stimulate CD4 + T cells
We compared TNF-matured DC from WT and B7-H1
2/2 mice regarding their surface markers and their stimulatory capacity. FACS analysis of these DC showed a comparable expression of CD80, CD86, CD40, MHC II and B7-DC (PD-L2) on their cell surface and despite the loss of B7-H1 in the knock-out mice ( Figure 1A ). We further investigated the potential of WT and B7-H1 2/2 DC to stimulate T cells. Therefore enriched CD4 + T cells derived from 2D2 mice bearing a TCR specific for MOG were co-cultured with MOG-loaded DC from WT and B7-H1 2/2 mice. The CD4 + T cells show comparable proliferation rates after incubation with WT or B7-H1 2/2 DC as indicated by CFSE-dilution ( Figure 1B ).
Higher tolerogenic potential of B7-H1
2/2 DC in EAE We previously demonstrated that repetitive i.v. injections of semi-mature DC, which were stimulated with TNF and loaded with MOG peptide, were able to protect mice from developing EAE [3] . Mechanisms involved in the mediation of tolerance revealed the induction of IL-10 producing CD4
+ T cells as well as the activation of NKT cells, which in turn rapidly produced protective cytokines contributing to the tolerogenic capacity of the semi-mature DC [2, 3] . To investigate the role of the coinhibitory molecule B7-H1 on tolerance induction we injected WT mice 7, 5 and 3 days before EAE induction with different numbers of MOG peptide loaded and TNF-matured WT and B7-H1 2/2 DC. We found that PBS-injected control mice developed severe EAE, whereas TNF-DC-injected mice were partially or fully protected from disease depending on the number and phenotype of applied TNF-DC (Figure 2A , Table 1 ). Mice injected with a suboptimal dose of WT TNF-DC (2610 6 ) displayed a slightly ameliorated EAE course compared to control animals, increase in TNF-DC numbers resulted in a more pronounced protective phenotype. In contrast, B7-H1 2/2 TNF-DC injected mice were fully protected from clinical signs of EAE, even at suboptimal doses of TNF-DC. To assess antigen specificity requirements for EAE tolerance induction, mice were treated with TNF-matured DC but without MOG before EAE induction. Here, no protective effect of both WT and B7-H1-deficient DC was observed, indicating that the induction of tolerance by injection of DC is neuroantigen-specific and dependent on the presentation of MOG peptide by DC ( Figure 2B ).
Injection of B7-H12/2 TNF-DC reduces the frequency of neuroantigen-specific cytokine-secreting T cells in the CNS
To address the amount of total T cell infiltration in the target organ of EAE-affected mice, we performed flow cytometry to quantify the abundance of CNS infiltrating T cells in the inflamed brains and spinal cords. 15 days after EAE induction an equal percentage of both CD4
+ and CD8 + T cell populations could be detected in all three investigated groups ( Figure 3A ). To further characterize the cytokine production by CNS-infiltrating T cells, ELISPOT analyses following MOG restimulation revealed highest frequency of neuroantigen-specific IFN-c and IL-17-producing cells in the CNS of PBS-injected mice ( Figure 3B ). WT TNF-DC injection resulted in a noticeable and consistent reduction of both IFN-c (92614 spots) and IL-17 (1565 spots) producing CNS cells, although the differences were not statistically significant in comparison to the control group (130611 spots for IFN-c, 1866 for IL-17) in two performed experiments. In contrast, using B7-H1-deficient TNF-DC injection prior to EAE induction, a marked decline in IFN-c positive spots to 2868 spots could be observed in the CNS of disease-protected animals. Again, the frequency of IL-17 secreting cells was reduced, but differences did not yield statistical significance (361 spots). CNS localized IL-10 production by MOG specific cells was also assessed but found undetectable in either group of mice (data not shown).
These data provide evidence that TNF-DC injection does not considerably influence total CNS T cell infiltration, but rather modulates the local cytokine milieu. Correlating to the EAE disease course, proinflammatory cytokines are substantially reduced upon B7-H1 2/2 TNF-DC administration.
Injection of B7-H1 2/2 TNF-DC modulates primary neuroantigen-specific T cell responses in the periphery
To assess the mechanism of increased EAE suppression in the absence of B7-H1 on tolerogenic DC, the spleens of PBS-or TNF-DC-injected mice were removed 10 days after EAE induction and peripheral T cell responses were investigated. Splenocytes were challenged with MOG peptide and after 72 hours cell culture supernatants were analyzed for their cytokine content by ELISA. In PBS-injected control mice the predominant cytokines that could be detected after MOG peptide titration were proinflammatory IFN-c and IL-17, whereas only little protective IL-10 and IL-13 were present ( Figure 4 ). By contrast, splenocytes from WT TNF-DC-injected mice produced large amounts of IL-10 and IL-13 even in the absence of or under low concentrations of neuroantigen. Simultaneously, secreted levels of IFN-c were similar to the control group and IL-17 was modestly reduced compared to PBS-injected mice. Interestingly, this TNF-DC-mediated effect on cytokine profile modulation was even more pronounced in the absence of B7-H1 on injected TNF-DC. Here, we found a markedly reduced production of IFN-c that was dependent on the MOG peptide concentration during spleen cell culture. Similarly, only small amounts of IL-17 could be detected in the supernatants. However, in B7-H1 2/2 TNF-DCinjected mice peripheral levels of IL-13 were dramatically increased compared to both PBS-and WT TNF-DC-injected mice. This effect was found to be only partially neuroantigenrestricted, as higher concentrations of MOG peptide further enhanced IL-13 production. High peripheral IL-13 concentrations were also accompanied by an increased basal amount of IL-10 in B7-H1 2/2 DC injected animals. Together, these data indicate that TNF-DC injections induce the production of protective cytokines and downregulates potentially pathogenic master cytokines. In correlation with the reduced disease courses, this effect is more distinct in the absence of B7-H1 on TNF-DC.
Injection of B7-H1
2/2 TNF-DC induces increased production of protective serum cytokines, which are predominantly produced by type II but not type I NKT cells
We showed previously that TNF-DC induce a rapid production of type 2 cytokines detectable in mouse sera early after the third injection of TNF-DC and their contribution to EAE prevention by constraining Th1 and Th17 effector cell development [2] . As a prerequisite we tested the PD-1 expression on the cell surface by type I and II NKT cells of WT mice and the type II NKT cells of Ja281 2/2 mice and could not find major differences ( Figure 5A ). To determine the relevance of TNF-DC B7-H1 expression for protective cytokine production, sera from WT or B7-H1 2/2 TNF-DC-injected mice were collected and analyzed for cytokine profile by ELISA. While IL-17 concentration was generally low and remained unaffected by TNF-DC treatment (data not shown), TNF-DC-injected mice displayed significantly elevated levels of IFN-c in their sera ( Figure 5B ). This effect was even reinforced in the absence of B7-H1 on TNF-DC. Simultaneously, IL-4 and IL-13 concentrations were markedly increased in WT TNF-DCinjected mice compared to control mice but significantly amplified using B7-H1-deficient TNF-DC. These findings are in line with the reduced disease course and support the notion of an increased induction of IL-4 and IL-13 producing cells in the absence of inhibitory B7-H1 on DC.
To identify the cell type responsible for increased IL-4 and IL-13 production upon transfer of TNF-DC, CD1d 2/2 mice as well as Ja281 2/2 were used as recipients of TNF-DC injections. CD1d 2/2 mice were described previously to lack type I and type II NKT cells, whereas Ja281 2/2 are deficient for the Vb14-Ja18 NKT (type I) cell population [28, 29] . After three injections of WT or B7-H1 2/2 TNF-DC in CD1d 2/2 mice serum samples were taken and subjected to cytokine quantification by ELISA. Although Ja281 2/2 mice have a bias towards high IFN-c and lower IL-4 and IL-13 secretion as compared to the other mouse strains, we observed comparable relative shifts for the production of the cytokines IFN-c, IL-4 and IL-13 in both TNF-DC-treated groups ( Figure 5B ). The absence of B7-H1 on TNF-DC did not lead to an augmented protective cytokine production in CD1d 2/2 mice. These data suggest an involvement of type I or II NKT cells in cytokine release. To further dissect the implication of these two cell subsets, we addressed selectively the role of type I NKT cells by using Ja281 2/2 mice. Serum ELISA revealed significantly increased IFN-c, IL-4 and IL-13 concentrations in the B7-H1 2/2 TNF-DC injected mice compared to WT TNF-DC-injected animals ( Figure 5B ). This indicates that type II NKT cells, but not type I NKT cells were the main producers of type 2 cytokines mediating protection from EAE.
Together, these data provide the first evidence of a direct inhibitory function of B7-H1 on TNF-DC for the induction of type II NKT cells and the loss of this negative signal is correlated with an amplified protective immune response.
NKT cell lines express PD-1 but only type II NKT cells are stimulated by DC and are negatively regulated by B7-H1
To further investigate if especially type II NKT cells were regulated by B7-H1 on DC we used different NKT cell lines, which were either related to type I (KT12 and BW58 r/m CD28) or type II NKT cells (XV19 and VIII24). All cell lines expressed PD-1, the ligand for B7-H1, at comparable levels ( Figure 6A ). We co-cultured DC from WT or B7-H1 2/2 mice with the different cell lines and found that only the type II NKT cells responded to the DC, which was indicated by the production of IL-2. Type Irelated cell lines did only respond to DC in the presence of the CD1d-ligand aGC. The IL-2 response of the type II-related cells was even higher in the absence of B7-H1 on the DC showing that B7-H1 negatively regulates these cell lines ( Figure 6B ). It is of note that also the type I NKT cell lines showed an increased IL-2 production in the presence of aGC by using DC that were generated from B7-H1 2/2 mice ( Figure 6B ).
Taken together we could show that DC only activated type II NKT cells by their endogenously expressed CD1d-ligands. This interaction was regulated by B7-H1 on the surface of the DC and independent of the PD-1 expression by the NKT cell lines.
Discussion
In this study we showed that absence of B7-H1 expression on semimature DC improves active tolerance induction upon DC injection into mice, which leads to the priming of protective peptide-restricted CD4 + T cells and CD1d-restricted type I and II NKT cells as well as the release of IL-10, IL-4 and IL-13. Injections of B7-H1 2/2 DC induced higher amounts of protective cytokines, specifically from type II NKT cells as indicated by the results from CD1d 2/2 and Ja281
mice. Thus, our data point to an inhibitory role of DC-expressed B7-H1 for type II NKT cells and MHC II/peptide-restricted CD4 + T cells but not type I NKT cells. The NKT cell line experiments may indicate a lack of endogenous CD1d-ligands on the DC for presentation to type I NKT cells but not type II NKT cells.
Tolerance induction by TNF-DC is predominantly dependent on the presence of the MOG-peptide loading and thereby on 
MHC II/peptide-restricted CD4
+ T cells, while CD1d-restricted NKT cells also contribute to the protection, however, by recognizing an endogenous CD1d-ligand from the DC that is irrelevant for the EAE [2] . Immediately after the third DC injection, CD4
+ T cells and NKT cells released IL-4 and IL-13 to create an immune-deviatory environment that counteracts the Th1 and Th17 effector cells which mediate EAE. However, the use of CD1d-deficient DC did not allow a distinction between responses of type I or II NKT cells. Subsequently during the response, IL-10-producing CD4 + T cells dominate among the MOG-peptide specific populations in the spleens of mice that were completely protected from EAE [3] . Intracerebral injections of semi-mature DC were also able to delay or prevent EAE, as higher numbers of IL-10-producing neuroantigen-specific lymphocytes were generated in the periphery, thereby restricting IL-17 production in the CNS [30] . The surprising finding was that obviously ''matured'' DC could still act tolerogenic, which did not fit into the paradigm of DC maturation where immature DC were postulated to be tolerogenic and mature DC to be immunogenic [31] . This dilemma could be best circumvented by the proposal of a third maturation stage that was termed semi-mature [1] . These semi-mature DC expressed high levels of costimulatory molecules such as CD80, CD86 and CD40, which were required for the EAE-protection since immature DC were unable to protect. In contrast to LPS-treated and thereby fully mature DC, semi-mature DC did not release proinflammatory cytokines and were generally described as low cytokine producers [3] . The question remained whether the additional expression of coinhibitory molecules on semi-mature DC could contribute to the tolerogenic functions.
We and others previously demonstrated that APC-derived B7-H1 plays a critical negative regulatory role to T cell stimulation in the context of autoimmune CNS inflammation [6, 15, 20, 21, 30] . Using B7-H1 2/2 mice in the MOG EAE model, earlier and exacerbated primary neuroantigen-specific immune responses were described ultimately leading to an aggravated disease course accompanied by higher immune cell infiltration in the CNS of B7-H1 deficient animals [21] . Thus, B7-H1 evolved as a crucial immune-inhibitory molecule capable of downregulating neuroantigen-specific T cell responses both in the periphery and the target organ of autoimmune inflammation. Recently, this concept was further corroborated by studies investigating the role of PD-1 ligands on different CNS APC applying a relapsing EAE model [22] . Therefore, we speculated that mediation of T cell tolerance induction might be altered in the absence of B7-H1 on APC [4, 11] . Surprisingly, we found here that in the absence of B7-H1 on the semi-mature DC their tolerogenicity was further enhanced. The enhanced release of protective cytokines could be attributed to the rare population of CD1d-restricted CD4 + T cells, so-called type II NKT cells. This is indicated by the use of specific type I and II NKT cell lines and the fact that the increased serum cytokine release of IL-4 and IL-13 after injection of B7-H1-deficient DC returned to the levels of mice injected with WT-DC when B7-H1-deficient DC were applied to CD1d 2/2 mice which lack both type I and II NKT cells. In contrast, Ja281 2/2 mice which lack only the Va14-Ja18 + type I NKT cells but not the type II NKT cells [29] , did show the serum cytokine increase. This is a strong indication that type II NKT cells are the predominant cell population that was affected by B7-H1 molecules on the DC. Type II NKT cells are selected in the thymus but on CD1d molecules instead of MHC II/peptide complexes. However, some authors found that they may not express markers typical for type I NKT cells such as NK1.1 [26, 27, 29] although this could not be confirmed in a type II NKT cell TCR transgenic mouse [32] . This may indicate the existence of NK1.1 negative and positive subtypes of type II NKT cells. A role for B7-H1 (PD-L1) interaction with PD-1 on type I NKT cells has recently been indicated to be responsible for the induction of an anergic state of type I NKT cells. This type I NKT cell anergy was defined as the fact that type I NKT cells become refractory for further stimulations by the ligand aGC after primary activation in vitro [24, 25] . The same anergic state is achieved after aGC injection in vivo [33] . However, we could not observe this when using CD1d-expressing DC for the type I and II NKT cell activation in vivo [2] . The discovery of sulfatide as an endogenous ligand for type II NKT cells that has been shown to influence EAE [34] and this may lead to anergy of type I NKT cells as shown in tumor and liver disease models [35, 36] . This opens the possibility that our DC may present sulfatide or a similar endogenous ligand to activate type II NKT cells leading to anergy or regulatory activity of type I NKT cells as discussed elsewhere [37] .
Additionally, the fact that aGC primed NKT cells also do not polarize selectively into IL-4 or IFN-c releasing cytokines in vivo but NKT cells do so when primed by differentially matured DC [2,38], 2/2 DC (2,5610 6 ) were injected i.v. into WT, CD1d2/2 or Ja281 2/2 mice three times (on day 24, 22 and 0). Similarly, control mice were injected with PBS. Blood was collected 2 hours after the last DC injection and serum cytokines were measured by ELISA for IFN-c, IL-17, IL-4 and IL-13. The results represent the average of 3 mice per group and are representative for 4 independent experiments for the WT mice and for 2 independent experiments for CD1d2/2 and Ja281 2/2 mice. * p,0.05, ** p,0.01, *** p,0.001, n.s. not significant. doi:10.1371/journal.pone.0010800.g005
indicates that the priming conditions by aGC or DC may differentially affect type I and II NKT cell responses. This may be explained by the fact that that in our previous experimental settings [2] , we did not distinguish between type I and II NKT cells. However here, by using the specific NKT cell lines it became clear that our in vitro generated DC do not carry an endogenous CD1d-ligand recognized type I NKT cell lines. In contrast, the same DC were readily detected by the type II NKT cell lines. However, type I NKT cells responded readily when pulsed with exogenous aGC. The differential capacities of our DC to stimulate type II but not NKT cells by an endogenous ligand raises the question, whether this presentation is due to the specific semi-mature stage of the DC. In our previous work we found already that BM-derived DC present an endogenous ligand on CD1d molecules [2] . Although we did not distinguish between type I and II NKT cells, these data clearly indicated that also LPS-maturation leads to the presentation of an unknown endogenous ligand. Therefore we speculate that a surrogate ligand, specific for type II NKT cells, is presented by DC to polarize these cells in a similar pattern as observed for Th1 and Th2 of MHC II restricted T cells.
Selective ligands for type I and II NKT cells may also point to differential interactions of CD1d-expressing APC populations in vivo. Especially CD1d high -expressing marginal zone B cells are also likely candidates to capture aGC after i.v. injection and to interact with type I NKT cells [39, 40] . Here we found that the CD1d-restricted CD4 + T cells are negatively regulated by B7-H1 when expressed by DC presenting an endogenous ligand but did not observe an effect on type I NKT cells in vivo or in vitro on the different NKT cell lines. In mice aGC injection leads to type I NKT cell-mediated DC maturation [41, 42] . All together, this indicates that the application of the surrogate antigen aGC has different antigenic and immunogenic properties as compared to physiological endogenous ligands by DC.
Together out data point to a novel role of B7-H1 molecules expressed by tolerogenic DC. Unexpectedly, B7-H1 inhibits selectively type II NKT cells but not type I NKT cells. In the absence of this coinhibitory molecule on tolerogenic DC even more protective cytokines are produced. Understanding the mechanisms of differential DC function and the impact of central coinhibitory molecules like B7-H1 in the context of CNS autoimmunity should help applying tolerogenic DC in targeted therapies. Selective induction of boosted tolerogenic properties of DC by modulating PD-1/B7-H1 interactions and thereby constraining induction and development of potentially pathogenic T cells might depict an attractive approach in cell-based therapy.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal practice as defined by the relevant national and/or local animal welfare bodies, and all animal work was approved by the appropriate committee (Regierung von Unterfranken, approval no. 55.2-2531.1-73/07).
Mice
Wild-type C57BL/6 mice were purchased from Harlan Winkelmann (Borchen, Germany). B7-H1 
Generation and maturation BM-DC
DC were generated from BM cells derived from C57BL/6 or B7-H1 2/2 mice as described [43] . Briefly, BM cell were flushed from femur and tibia and cultured with 10% supernatant of a GM-CSF producing cell line and used at day 6-10 of culture. For DC maturation, cultures were pulsed for 4 h with TNF (500 U/ml; PeproTech) together with MOG peptide before intravenous injection into the tail vein of mice.
T-cell proliferation assay
BM-DC from WT and B7-H1
2/2 mice were stimulated with TNF and loaded with MOG 35-55 as described above. MOG 
Induction of EAE and injections of DC
MOG peptide (EVGWYRSPFSRVVHLYRNGK; synthesized and HPLC purified by R. Volkmer, Charite, Berlin, Germany) was used for active induction of EAE. Age-and sexmatched C57BL/6 or CD1d 2/2 mice were immunized s.c. with 200 mg MOG emulsified in CFA (Sigma-Aldrich, Steinheim, Germany) that was further enriched with Mycobacterium tuberculosis H37RA (5 mg/mL) (Difco, Detroit, MI, USA). In addition, mice were injected i.p. with 400 ng pertussis toxin (List Biological Laboratories, Laboratories, Campbell, CA, USA) at the time of immunization (day 0) and 48 h later. Using this standard immunization protocol, we observed a typical chronic disease course, for which clinical signs of disease were monitored daily and scored based on the following scale (EAE score): 0, no disease; 1, limp tail; 2, hind limp weakness; 3, hind limp paralysis; 4, hind and fore limp paralysis; 5, moribund or death. 2-3610 6 stimulated and MOG pulsed DC were injected intravenously repeatedly at days 27, 25 and 23 before EAE induction (day 0).
Isolation of spleen cells and preparation of CNS mononuclear cells
For isolation of CNS mononuclear cells, mice were perfused through the left cardiac ventricle with cold PBS, brains were dissected and spinal cords were flushed out with cold PBS. CNS material was cut into pieces and mononuclear cells were recovered from the interface of a 30-50% percoll gradient centrifuged for 30 min at 5000 rpm. Cells were washed and resuspended in culture medium for further analysis.
Single cell suspensions of splenocytes were obtained by mashing the spleens of donor mice through a 70 mm strainer and subsequent lysis of red blood cells with ACK buffer (150 mM NH 4 Cl, 10 mM KHCO 3 , 0,1 mM EDTA). Splenocytes were cultured in serum-free HL-1 medium (Lonza) supplemented with Penicillin (100 U/ml, PAA), Streptomycin (100 mg/ml, PAA), L-Glutamin (2 mM, PAA) and b-mercaptoethanol (50 mM, Sigma).
Flow cytometry
BM-derived DC, NKT-cell cell lines, Splenocytes or CNS derived cells were stained with surface antibodies (anti-B7-H1-PE, anti-CD80-FITC, anti-CD86-FITC, anti-CD40-PE, anti-MHC II-PE, anti-CD3-FITC, anti-NK1.1-PerCP-Cy5.5, purchased from BD Pharmingen; anti-B7-DC-PE, anti-PD-1-PE, anti-CD4-PerCp, anti-CD8-PE, purchased from eBioscience) in the presence of FccRII/FccRIII-specific antibody (clone 2.4G2) to block unspecific binding. FACS datawere collected on FACS Calibur cytometer (BD Biosciences) and analyzed using FlowJo software (TreeStar) version 7.2.1.
ELISA and ELISPOT
For the measurement of cytokine responses by ELISA, 4610 5 splenocytes depleted from erythrocytes were cultured in vitro in the presence of different concentrations of MOG peptide (0-20 mg/ml) and supernatants were collected after 3 days. Sera were collected 2 h after the third immunization. Samples were analyzed for cytokine content using ELISA kits for IL-4, IL-10, IFN-c (BD Pharmingen), IL-13 and IL-17 (eBioscience).
For ELISPOT assays, 5610 4 CNS cells per well were stimulated with 10 mg/mL MOG peptide and cultured for 24 h in 96-well-plates. ELISPOT assay was performed according to the manufacturer's instructions (for IFN-c: BD Pharmingen; for IL-17: eBioscience). Spots were counted using a Wild Heerbrugg M3Z dissecting microscope or evaluated by CTL Europe GmbH (Aalen, Germany).
NKT cell line assay
The following NKT cell lines were used: KT12 [44] , VIII24 and XV19 [26] , BW58 r/m CD28 [45] . NKT cell lines were cultured in RPMI with L-glutamin (GIBCO) containing 5% FCS, 100 U/ml Penicillin/Streptomycin, 0.1 mM non-essential aminoacids, 1 mM Na-pyruvate and 5 mM b-mercaptoethanol. For the co-culture experiments the cell lines were cultured with TNFmatured DC derived from WT or B7-H1 2/2 mice in medium containing GM-CSF. 5610 4 cells from the cell lines KT12, BW58 r/m CD28 or VIII24 or 1610 4 cells from the XV19 cell line in an 96 well plate (round bottom) for 24 hours with the DC. As positive control 10 ng/ml aGC (Alexis Biochemicals) was added to the culture. The supernatant of this culture was testet by ELISA for IL-2 production (BD Pharmingen).
Statistical analysis
Two-tailed Student's t-test was used to determine the statistical significance of difference. A value of p,0.05 was considered significant. Error bars in figures represent standard deviations.
